These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23172636)

  • 1. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis.
    Tawbi HA; Beumer JH; Tarhini AA; Moschos S; Buch SC; Egorin MJ; Lin Y; Christner S; Kirkwood JM
    Ann Oncol; 2013 Apr; 24(4):1112-9. PubMed ID: 23172636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
    Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
    Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
    Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide and cisplatin in avdanced malignant melanoma.
    Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
    Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
    Gogas H; Polyzos A; Stavrinidis I; Frangia K; Tsoutsos D; Panagiotou P; Markopoulos C; Papadopoulos O; Pectasides D; Mantzourani M; Middleton M; Vaiopoulos G; Fountzilas G
    Ann Oncol; 2006 Dec; 17(12):1835-41. PubMed ID: 16980601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
    J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
    von Moos R; Seifert B; Simcock M; Goldinger SM; Gillessen S; Ochsenbein A; Michielin O; Cathomas R; Schläppi M; Moch H; Schraml PH; Mjhic-Probst D; Mamot C; Schönewolf N; Dummer R;
    Ann Oncol; 2012 Feb; 23(2):531-6. PubMed ID: 21527587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
    Schadendorf D; Hauschild A; Ugurel S; Thoelke A; Egberts F; Kreissig M; Linse R; Trefzer U; Vogt T; Tilgen W; Mohr P; Garbe C
    Ann Oncol; 2006 Oct; 17(10):1592-7. PubMed ID: 17005632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
    Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
    Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
    Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
    Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
    Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
    J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
    J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
    Bael TE; Peterson BL; Gollob JA
    Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
    Dronca RS; Allred JB; Perez DG; Nevala WK; Lieser EA; Thompson M; Maples WJ; Creagan ET; Pockaj BA; Kaur JS; Moore TD; Marchello BT; Markovic SN
    Am J Clin Oncol; 2014 Aug; 37(4):369-76. PubMed ID: 23357973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.
    Middleton MR; Friedlander P; Hamid O; Daud A; Plummer R; Falotico N; Chyla B; Jiang F; McKeegan E; Mostafa NM; Zhu M; Qian J; McKee M; Luo Y; Giranda VL; McArthur GA
    Ann Oncol; 2015 Oct; 26(10):2173-9. PubMed ID: 26202595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Tsoutsos D; Kalofonos H; Chalkidou S; Panagiotou P; Linardou E; Briassoulis E; Efstathiou E; Polyzos A; Fountzilas G; Christodoulou C; Kouroussis C; Iconomou T; Gogas H
    Ann Oncol; 2005 Jun; 16(6):950-7. PubMed ID: 15829494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.